Arcadia Biosciences Announces Fourth-Quarter and Full-Year 2019 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Arcadia Biosciences (RKDA) Misses Q4 EPS by 15c, Revenues Miss
March 25, 2020 4:12 PM EDTArcadia Biosciences (NASDAQ: RKDA) reported Q4 EPS of ($0.72), $0.15 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $416 thousand versus the consensus estimate of $590 thousand.
"We are energized by our progress in hemp, wheat and soy in 2019 and the strength with which we enter 2020 to grow our GoodHempTM seed sales, Hawaiian CBD oils, and GoodWheatTM flour and grain sales," said Matthew Plavan, president and CEO. "Moreover, as we take stock... More
